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Abstract
In the PREPA observational study, we investigated the factors influencing pharmacoki-
netic and pharmacodynamic variability in the response to fluindione, an oral anticoagulant
drug, in a general population of octogenarians inpatients.
Measurements of fluindione concentrations and INR (International Normalised Ratio)
were obtained from 131 inpatients initiating fluindione treatment. Treatment was adjusted
according to routine clinical practice. The data was analysed using non-linear mixed effect
models, and the parameters were estimated using MONOLIX 3.2.
The pharmacokinetics of fluindione was monocompartmental, while the evolution of INR
was modelled according to a turnover model (inhibition of vitamin K recycling). Interindi-
vidual variability was very large. Clearance decreased with age and with prior administration
of cordarone. Patients who underwent surgery before the study had lower IC50, leading to
an increased sensitivity to fluindione.
Pharmacokinetic exposure is substantially increased in elderly patients, warranting a
lower dose of fluindione.
Keywords: fluindione; antivitamin K; oral anticoagulant; elderly; pharmacokinetics; pharma-
codynamics; International Normalised Ratio (INR)
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1 Introduction
Evidence-based clinical practice guidelines recommend vitamin K antagonists in the preven-
tion of stroke in atrial fibrillation [1, 2], in the treatment of venous thromboembolism [3], in
patients with mechanical valve and in the first 3 months following bioprotheses implantation [4].
Despite their proven benefit, studies attest to their underutilisation particularly among elderly
individuals [5, 6]. Antivitamin K agents (AVK) act by inhibiting the reduction reactions by
which the vitamin K is recycled, in turn decreasing the synthesis of vitamine K-dependent co-
agulation factors (factors II (prothrombin), VII, IX, X, protein C, and protein S) [7]. The two
main classes are coumarin derivatives, including warfarin and acenocoumarol, and indanedione
derivatives, including fluindione and phenindione. Fluindione constitutes about 80% of AVK
prescriptions in France [8].
AVK are characterised by a large between-, but also within-patient variability in the dose-
response relationship. The therapeutic window is narrow, so that clinicians must walk a thin line
between suboptimal dosage risking thromboembolic events and higher doses potentially risking
bleeding episodes. The frequency and seriousness of haemorragic adverse events varies in the
literature, depending on the population, the prescribed therapeutic range, the other treatments
co-administered and the duration of treatment with AVK [9]. The Adverse Event Reporting
system of the US Food and Drug Administration provides evidence that warfarin is among the
top 10 drugs with the greatest number of serious adverse events. In France, where the present
study was performed, iatrogenic events due to oral anticoagulant drugs represent the first cause
of hospital admission for drug-related adverse event [10], totalling about 17000 admissions a year,
and an estimated 3000 to 5000 deaths [11]. A meta-analysis of available clinical trials in patients
anticoagulated for venous thromboembolism, reported a case-fatality rate of major bleeding of
13.4% in all patients (95% confidence interval 9.4 to 17.4%) [12]. Haemorragic events are overall
more frequent and more severe in elderly patients compared to the general population [13]. The
contribution of age per se to this increased risk is somewhat controversial, some studies pointing
to an increase of the incidence of haemorragic events as a function of age [9] while others do
not find it significant [14], but the fact that severity increases with age is undisputed [15] so
that scores developed to predict the risk of bleeding include age over 65 as an independent
risk factor [2, 16]. The main risk factors known to bring about haemorragic complications
are level of anticoagulation, poor quality of monitoring, lack of patient eduction, associated
comorbidities and comedications, including interactions with drugs interfering with haemostasis,
and being in the first months of treatment [9, 14, 17]. Variability in International Normalised
Ratio (INR) levels is also higher in elderly patients [18, 19]. A large part of this variability
can be explained by changes in the dose-concentration relationship (pharmacokinetics, PK),
or in the concentration-response relationship (pharmacodynamics, PD). Measurement of AVK
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concentrations can contribute to a better understanding of these two components by separating
these two contributions.
In the present paper, we describe the findings from the PREPA study, investigating the
pharmacokinetics and pharmacodynamics of fluindione in octogenarians using non-linear mixed
effect models. The primary objective of PREPA was to study the factors influencing the source
of variability in the response to fluindione in elderly inpatients starting fluindione, with a special
interest in comorbidities and comedications.
2 Results
2.1 Data
151 subjects were recruited in PREPA, 131 of whom provided PK/PD data and were included
in the present PK/PD analysis. Table 1 shows the demographic and biologic variables recorded
in this population.
The prescribed therapeutic range for INR was [2-3] for all the patients included in the study.
The elderly patients included in the PREPA study were generally polymedicated: on the first
day of the study, they received on average 8 different medications in addition to fluindione. In
this study, initial dosing of fluindione was conservative: the initial dose was 5, 10 and 15-20 mg
in 28, 94 and 10 subjects respectively. The median duration of stay in the study was 8 days
(range 2 to 31 days). The last dose of fluindione was 5 mg or less for 32 subjects, 7.5-10 mg
for 54 patients, 12.5-15 mg for 30 patients and 17.5-22.5 mg for 15 patients. There were large
variations between the initial and final dose (correlation 0.25), with the dose unchanged in 44
subjects (34%) while 32 had a lower dose (24%) and 55 a higher dose (42%). This study was
not designed to evaluate a maintenance dose of fluindione, and only 52 patients (40%) left the
study with an INR between 2 and 3.
Ten subjects (8%) experienced bleeding during the study, as described elsewhere [20]. Nine of
these patients also received heparin prior to initiating fluindione treatment, and severe bleeding
occurred in 5 of them, always associated with the heparin treatment. The tenth subject, who
suffered from hemorroids and constipation, started heparin on day 2 and experienced minor
bleeding the next day, which resolved quickly.
2.2 Base model building
The PK dataset included 493 concentrations of fluindione, and the PD dataset 477 measure-
ments of INR. A one-compartment model without lag-time provided an adequate fit to the PK
data, based on tests and diagnostic graphs. Although the estimation error for the absorption
rate constant ka was reported as reasonable, its interindividual variability (IIV) was large, and
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this parameter proved relatively unstable from run to run, especially at later stages when co-
variates were included in the model. Because there was little information about the absorption
phase, we considered a model where ka was fixed without variability. In a study in healthy
volunteers, fluindione was found to be quickly absorbed, with an average Tmax of 2.0 h (range
0.5-6.0 h) [21], while the elimination half-life was 35 h (SD 6.5 h). Based on these figures, we
fixed ka to 2.42 hr
−1. This improved model stability, and provided similar estimates of V and
CL. IIV was estimated for CL and V, without covariance.
An indirect response model for 1/INR was found adequate in the PK/PD analysis. INR
values increase from baseline value of 1 in a normal patient, and the estimate of the additive
part of the combined error model converged to a very small value. Therefore the residual
variability for the INR model was modelled as proportional. A diagonal covariance matrix was
used to model IIV. The Hill coefficient was significantly different from 1, and assuming a linear
model instead of the Imax model also degraded the fit. Models including precursors were also
tested to account for time delays but did not improve the fit or the likelihood.
2.3 Covariate model building
Covariates were first included on V and CL. Using the individual parameters estimates from
the base model, the following covariates were found to have an influence on V, CL or both, and
were considered for inclusion in the model: gender, weight, age, surgery, atrial fibrillation, renal
function, Mini-Mental State (MMS) score, as well as administration of cordarone and deroxat.
After pruning down the model, the following relationships remained: the volume of distribution
V was found to increase with weight, and to be higher in men; clearance CL on the other hand
was found to decrease with age, and to be lower in patients who received cordarone during the
study. We also explored the relationships between parameters and time-varying comedications
by considering each occasion as a separate subject. None of these comedications was found to
influence the two PK parameters.
For the PD parameters, the following candidate relationships were found: CLCR, nonagerian,
surgery and protamine on I0, deroxat on Imax, CLCR, surgery and protamine on kout, nonagerian,
surgery and protamine on C50, Activities of Daily Living (ADL) score, surgery and deroxat on
γ. In the final model, patients recovering from cardiac surgery were found to have reduced C50
and γ, translating to higher sensitivity. These patients were younger but age did not remain in
the model. Deroxat increased γ.
The variability on Imax was poorly estimated and was removed from the final model. In most
models we found I0 to be very close to 1, but the assumption I0=1 led to a significant increase
in the statistical criterion.
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2.4 Final model
Table 2 shows the parameter estimates for the base and final model (the range obtained
by multiple imputation is given in Supplementary Table S2, showing the robustness of the
estimates). There was a small decrease in the estimates of the variabilities of all parameters
except kout when including covariates in the model, however the IIV remained large. Relative
standard errors were less than 10% for the main parameters, and within a 10-30% range for
the variability of the random effects. Compared to women, men had an apparent volume of
distribution increased by about 25%. The increase of V with weight was relatively small, since
an increase of 10 kg in weight translates to about 9% increase in V. The decrease of CL with
age is more relevant, since we expect a 90 year old patient to have a clearance reduced by 30%
compared to a 80 year old patient, and patients who received cordarone had a 20% decrease in
clearance. Prior surgery both increased the sensitivity to fluindione, reflected by a 50% reduction
in IC50, and decreased the sigmoidicity coefficient γ by about 50% so that the increase in the
concentration-response curve is more gradual in these patients. The influence of deroxat on γ
was the opposite, with a steeper curve for these patients indicating an on/off type of response.
We performed a small stability study to assess the ability of the sparse design to estimate
the PK parameters, and found that CL and V could be correctly estimated (see Supplementary
Material), consistent with the low correlations reported between the estimates of the PK pa-
rameters (-0.16 for the correlation between the estimates of V and CL). The correlations were
higher between the PD parameters of the Imax model (corr(IC50,Imax)=0.6 and corr(IC50,γ)=-
0.73), suggesting that the design may not be as informative for the PD. All other correlations
were lower than 0.35. The robustness of the estimates was checked by changing seeds and initial
conditions. Shrinkage was large for most parameters, reflecting the relative lack of information
in this sparse design: V (44%), CL (32%), IC50 (47%), kout (63%), I0 (86%) and γ (80%). The
-shrinkage was 31% for PK and 39% for PD.
Diagnostic plots are shown in figures 2 and 3. Graphs of the npde (normalised prediction
distribution errors) versus time and dose, which are more appropriate than VPC because of the
heterogeneous design [22, 23], are shown in Figure 3; prediction bands have been overlayed to
indicate model predictions. The two upper graphs show the npde versus time, for fluindione
(left) and INR (right), and indicate good model adequacy for fluindione, while for INR the model
slightly underpredicts the last time-point. The two lower graphs show the npde versus model
predictions; the model can be seen to perform adequately on average both for PK and PD, while
variability is sometimes under or overestimated. Individual graphs are shown for 12 subjects
from different clinical departments (Figure 4: fluindione concentrations; Figure 5: INR). The
dotted line in the individual plots for INR show the target therapeutic range, while vertical bars
are drawn to show the doses received (the scale for doses is on the right-hand axis). For most
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subjects, the model is able to reproduce both PK and PD measurements adequately, describing
even complex profiles. In a few cases, (eg subject 1086, topmost panel, right), the PK is very
well predicted but the PD shows unexplained fluctuations, with INR starting to decrease despite
stable doses and concentrations.
Using the steady-state approximation with the population parameters, we found that doses
of 7.5 and 10 mg ensure an INR within the therapeutic range for a typical patient (weight 65 kg,
age 85 kg), regardless of gender. IIV however is large, and often at least 2 doses provide an
INR within the range. Table 3 shows dose recommendations depending on individual covariates,
obtained by simulations under the model. In each setting, when taking into account IIV, this
average dose is valid in about 20% of the simulations, while a dose within +/-2.5 mg of this
dose is recommended in about 50% of the simulations.
3 Discussion
Fluindione is an AVK used mostly in France, where it is regarded as an interesting alternative
to the warfarin; contrary to warfarin, fluindione is not a racemic mixture and its longer half-life is
considered to help stabilise INR levels [24]. As other anticoagulant drugs however, it is a difficult
drug to adjust. In a previous study called ADAP, we investigated the pharmacokinetics and
pharmacodynamics of fluindione in a general population of patients initiating treatment [25, 26].
In these younger patients (mean 60 years, range 29–89), we demonstrated not only large IIV,
but also, through a follow-up study recording dose changes and evolution of anticoagulation
after discharge from the hospital, a sizeable intraindividual variability. This variability led to
fluctuations in the anticoagulation level even in patients thought to be stabilised when leaving
the hospital [27].
In the present study, we used a PK/PD model closely related to the one developed in ADAP.
The main differences are the absorption model, which was previously assumed to a bolus dose
and which we fixed here, and the use of a Hill model to represent drug effect. The estimates
of CL and V were very close to the value estimated assuming an IV bolus, but the statistical
criterion was slightly better with an oral absorption phase. The estimates of the PK parameters
however are quite different from previously [25, 26]. In the final model, V was estimated to be
around 8 L, while CL was 0.1 L.hr−1. In the ADAP study on the other hand, we estimated these
parameters to be respectively 37 L and 0.49 L.hr−1. Both sets of parameters however give the
same estimate for half-life, 56 h versus 52 h previously. The increased exposure was also apparent
in the measured concentrations: in the ADAP study, subjects received daily doses of fluindione,
with starting doses of 15 to 20 mg, and concentrations after 5 days of treatment were around
0.8 to 1.2 mg.L−1, while in PREPA concentrations at day 5 range from 1 to over 8 mg.L−1
as shown in figures 1 and 4. In addition, starting doses were lower, most patients receiving
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10 mg initially or less. Thus, compared to the previous study, we observe a marked increase in
the exposure to fluindione. Since fluindione is administered orally, the reported V and CL are
apparent parameters, so an explanation to this discrepancy with previous results is a difference
in bioavailability between the two studies. However, this would require a more than four-fold
increase in bioavailability in elderly patients compared to the younger population previously
studied. Fluindione is to some extent cleared by the liver, with the hepatic metabolism of
fluindione appearing to be mediated by CYP2C9 [28], but is mainly renally excreted, so that we
do not expect first-pass effect to be a major determinant of drug concentrations; the increase in
drug exposure would then be driven by a dramatic increase in the absorption process. Changes
in plasma protein binding could be another possibility. For all drugs eliminated primarily by the
liver total exposure is independent of protein binding but, like fluindione, oral drugs eliminated
by nonhepatic high extraction ratio routes exhibit changes in unbound drug exposure when
protein binding changes. This would not be expected to affect exposure to such an extent since
fluindione does not exhibit a particularly high extraction ratio [29]. The smaller volume of
distribution might be the consequence of the combination of a lowered volume of tissue with
an increase of the fraction unbound in tissue (V=Vp + Vt fu/fut), both clinically relevant in
an elderly population with a lipophilic drug [30]. Modification, either increase or decrease, of
transit times in this heavily medicated population could also explain an increase in the fraction
absorbed by changing the dissolution of fluindione; indeed, 117 patients (89%) received drugs
modifying transit, and slower intestinal transit times are frequently observed in the elderly. The
alteration in PK exposure could therefore be due to a combination of factors [30] and warrants
further exploration in a controlled study.
Dose reduction with age is also observed for other oral anticoagulants [18, 24]. The latter
study, although admittedly retrospective, included over 22 000 patients, and found that patients
aged 80 years or older required doses one-third to one-half of those given to patients younger than
50. For fluindione, Mahe´ et al. observed in a retrospective study that patients over 75 years old
required a lower dose of fluindione than younger patients for a comparable INR [31], which can be
interpreted as due to modifications in exposure in the light of our results. For the PD parameters,
we found an estimate of IC50 about 60% higher than in the ADAP study (2.18 mg.L
−1 instead
of 1.35 mg.L−1), but still within the same range, suggesting that elderly patients have a similar
sensitivity to fluindione despite having an increased exposure. The present study provides a
rationale explaining the findings of others that lower doses are required in elderly patients, by
linking them to PK, and underscores the importance of having both PK and PD measurements
in order to separate pharmacokinetic and pharmacodynamic changes. kout on the other hand
was noticeably smaller (0.03 versus 0.18 hr−1), indicating a slower turnover than in younger
patients.
We used the model and parameter estimates to predict a dose that should be given in order to
8
Comets et al.
maintain an INR within the therapeutic range at steady-state. Consistent with the observation
that the concentrations were higher in this population of elderly patients than in the population
we previously studied [25, 26], the model predicted relatively low doses, suggesting a daily 10 mg
dose, or an alternance of 5 and 10 mg doses, should be a safe starting dose for most patients.
This is also in line with the maintenance doses observed in the retrospective study by Mahe´ [31].
Fluindione however is still packaged as 20 mg pills, which are in practice difficult to divide for
routine treatment.
The present study was targeted towards elderly patients during hospitalisation, since this
population is both more likely to receive anticoagulant drugs and more fragile, being often
polymedicated and with comorbidities. These patients are therefore more susceptible to bleeding
and dose adjustment for oral anticoagulants is particularly difficult [32]. Given its observational
nature and the short duration, the PREPA study was not specifically designed to investigate
risk factors for clotting or bleeding; a more detailed analysis of the 8 bleeding events which
occurred in the subset of patients with atrial fibrillation can be found in [20]. A major objective
of the present study was to identify covariates that could explain some of the variability in the
response. We found the pharmacokinetic parameters to be influenced by gender, weight and age,
as well as prior administration of cordarone (amiodarone) while the only covariates influencing
pharmacodynamic parameters were prior surgery and administration of deroxat. We did not
find any relationship with time-varying comedications, but this may be due to the heterogeneity
of the population and to the small sample size. Cordarone has been reported to increase the
haemorragic risk [33], which could relate to the 20% reduction we find, translating into an
increased exposure. We did not find a relationship with anti-infective agents (antibiotics and
anti-fungal drugs) as in that study; nearly half of the patients received an antibiotic at some point
during treatment, but it is possible that the analysis could not pick up a relationship especially if
the influence is delayed, since we considered only an on/off type of relationship. Also the sample
size was too small to consider each drug separately so we pooled the different antibiotics and
the different dosages for the analyses. About a third of the patients took part in the optional
pharmacogenetic study. We found no relationship between the 3 genetic polymorphisms and PK
or PD parameters. The influence of CYP2C9 on PK through metabolism has been described
for warfarin [34]; for fluindione, a recent study in healthy volunteers showed a lower clearance
in carriers of the *3 allele [28], while the influence on the response is expected to be related to
VKORC1 [35, 28]. We were not able to confirm these relationships here, perhaps due to the
small number of subjects.
Most patients did not remain in the study long enough to reach a stable INR. However, even
within the duration of their stay, we noted that dose changes occurred too often and sometimes
irrationally. In particular, the long time-course of INR evolution after AVK did not appear well
anticipated by the prescribing clinicians. This is apparently partly due to a lack of follow-up,
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as doses are frequently modified based only on the latest INR, without considering the pattern
of doses given and INRs measured since the beginning of the treatment. In several countries
specialised anticoagulation clinics have been set up to help manage anti-vitamin K drugs and
have been shown to improve management of anticoagulation treatment [8]; a pilot clinic now
exists in France [36]. A perspective of the present work could be to develop a software helping
clinicians to anticipate the future evolution of anticoagulation, by producing plots based on
individual INR measurements and dosing regimen [37, 38].
In conclusion, the PREPA observational study highlighted that dose adjustement for AVK
agents is still a major issue, especially in the elderly. The complexity of INR dynamics and the
resulting delay between the time-course of the drug and the clinical variations of anticoagulation
levels make it difficult to anticipate changes in INR, so that adjustements in doses must be
made after taking into account the evolution over several days and not a single measurement.
Elderly patients should be treated as a special population presenting a noticeably increased
pharmacokinetic exposure to the drug. They should receive significantly lower doses and the
onset of treatment should remain conservative.
4 Methods
4.1 Data
The PREPA study was a prospective, observational multicenter study conducted between
September 2005 and September 2007, recruiting consecutive patients hospitalised in 6 medical
and 1 surgical (cardiac) acute-care units from 3 French hospitals. Patients, 80 or older, were
prescribed fluindione after at least 2 weeks off oral anticoagulants. Exclusion criteria were:
contraindication to fluindione treatment due to hypersensitivity to indanedione derived drugs,
incompatible comedication, inclusion in another therapeutic trial, expected length of stay in
hospital less than 3 days. The study was approved by the Ethics committee from Hospital
Europe´en Georges Pompidou (HEGP), and all participants provided written informed consent
in accordance with the Declaration of Helsinki. The clinical trial has been registered on the
public registry ClinicalTrials.gov.
Patients were followed by clinicians according to the local clinical practices. In particular,
doses were adjusted based on routine measurements of INR, without using any dosing algorithm.
Fluindione was administered in the evening, usually around 6 p.m. Blood samples for the mea-
surement of INR were taken in the morning, according to the usual practice in the participating
centers for therapeutic monitoring: before the first administration of fluindione (day 0), and
after 2, 4, 6 and 8 doses of fluindione; additional samples were obtained twice a week after that
for therapeutic monitoring. The date of each sample was recorded by the nurse, and the time
of the sample when it was outside of the window 9-11 a.m. Each time a blood sample was
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taken for the measurement of INR and coagulation factors, an additional 5 mL blood vial was
drawn for measuring fluindione concentrations, except at day 0, where fluindione concentrations
were measured only in patients who had received a dose of an oral anticoagulant within the two
weeks immediately preceding the first dose of fluindione in the study. As an ancillary optional
study, which required a separate informed consent, an additional blood sample was taken for
genotyping. Genetic polymorphisms for two CYP2C9, which are known to influence the phar-
macokinetics of warfarin [34] and acenocoumarol [35], as well as a genetic polymorphism in the
gene coding for vitamin K epoxide reductase complex subunit 1 (VKORC1) [39], the target
of AVK treatment and involved in the response [40], were determined. Analytical details are
available in the Supplementary material.
For each patient, the following variables were recorded at the inclusion visit by a clinician
involved in the study: age, gender, weight, weight changes within the 6 months preceding the
inclusion visit, ADL, Charlson comorbidity score, MMS, reason for fluindione treatment, ther-
apeutic range for INR, major comorbidities, cardiac surgery. A number of biological variables
were also measured at baseline: albumin, C-reactive protein (CRP), haematocrit levels, proti-
daemia, natremia. Creatinine clearance (CRCL) was computed from age (year) and creatinine
clearance using the following formula [41]:
CRCLMDRD(µmol/l) = 186 (0.0113 CREAT)
−1.154 Age−0.203 (1)
Renal function was classified as normal (CLCR≥60 ml/mn), moderately impaired (CLCR be-
tween 30-60 ml/mn) and severely impaired (CLCR<30 ml/mn).
Patients were defined as suffering from malnutrition when they had recent severe weight loss
(over 10% of weight), a body mass index lower than 18, or albumin levels lower than 30. Finally,
high levels of CRP (CRP>50 mg.L−1) were considered to be a sign of current hypercatabolism.
One important objective in this group of elderly inpatients was to describe and take into
account the many comedications these patients received. Comedications given to each patient
were recorded at the initial visit, and changes were documented throughout the study. Comed-
ications received were classified according to their influence on INR, using the classification
proposed by Holbrook [42] (given in Supplementary Table S2). Drugs were first classified ac-
cording to whether they increase the thrombotic risk or the haemorragic risk; the second group
was divided further into drugs increasing the INR (class B2) versus drugs acting independently
(class B1). Nonsteroidal anti-inflammatory drugs (group B12) and diuretics were also considered
for their potential effect on pharmacokinetic parameters. For each class and each subject, we
defined a daily indicator variable. Cordarone, amiodarone and deroxat, because of their long
half-life, were considered separately and assumed to remain active for 1 month (cordarone and
amiodarone) and 15 days (deroxat). Only therapeutic classes which were received by at least 10
and at most 122 patients were considered in the analysis.
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4.2 Model building
Non-linear mixed effect models were used in this analysis; the jth observation in subject i,
yij, is modelled as:
yij = f(xij, ψi) + g(xij , ψi)ij (2)
where ψi denotes the individual parameters, f the structural model and g the residual error
model (ij ∼ N (0, 1)). We assume that ψi depends on individual covariates ci, a vector of fixed
effects µ and a vector of individual random effects ηi through a function h:
ψi = h(µ, ci, ηi) (3)
The parameters were estimated through the Stochastic Approximation EM algorithm (SAEM)
implemented in the MONOLIX software [43] (version 3.2, release 1), running on a Linux PC
(Kubuntu 10.10). All other statistical analyses were performed in R (2.11) [44].
Base model selection. We first studied the PK of fluindione alone. The residual variability
was modelled using a combined error model. The structural model was built by selecting the
best model amongst one and two-compartmental models with first or zero-order absorption,
with or without lag-time.
The evolution of INR was modelled using a turnover model, describing the evolution of
coagulation factor activity F (t) = 1/INR(t) through the following equation:
dF (t)
dt
= Rsyn
(
1− Imax
C(t)γ
C(t)γ + ICγ50
)
− kout F (t) (4)
The model was parameterised in terms of kout and INR0 = 1/F0 where, in the absence of drug,
we have the relationship: F0 kout = Rsyn.
Imax was assumed to follow a logit distribution while all the other parameters had a log-
normal distribution. For each parameter we tested whether IIV could be removed from the
model, and we also tested correlations between parameters by introducing covariances. To
select structural and variability models, we used appropriate likelihood ratio tests (LRT), based
on the log-likelihood computed using importance sampling.
Covariate model building. We examined the relationships between parameters and covari-
ates, first in the PK model alone, then in the PK/PD model. Covariate model building was done
by exploring the relationships between covariates and estimated individual parameters (obtained
as the conditional modes of the individual distribution) through linear regression for the contin-
uous covariates and parametric tests for the categorical covariates; all candidate covariates were
included in a full model, using power functions for continuous covariates; the model was then
pruned down by removing covariate effects for which the p-value of the Wald test was larger
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than 0.05, starting with the covariates which had the largest p-value. A non-significant Wald
test indicates a high estimation error for the corresponding parameter. The same approach was
used for the full PK/PD model with the best PK model, re-estimating all parameters. The final
PK/PD model was evaluated using standard diagnostic graphs provided by MONOLIX. We also
computed the shrinkage, as, for the kth- parameter:
Shk = 1−
var(ηˆ
(k)
i )
ω2k
(5)
where ηˆ
(k)
i is the estimated kth random effect in subject i. The -shrinkage was computed
separately for PK and PD:
Sh = 1− var(IWRESij) (6)
where IWRES denotes the individual weighted residuals. In the presence of high shrinkage,
diagnostic plots based on individual estimated parameters are less informative [45].
Covariates missing in more than 14 subjects (10%) were excluded from the analysis; the
other missing covariates were imputed to the mean value for continuous variables and to a value
randomly sampled for the discrete covariates. The final model was checked using multiple im-
putation [46], using the package mice for R [47]. An additional exploratory analysis investigated
relationships between the PK/PD parameters and the genetic covariates in subsets of the data.
Steady-state dose. Fluindione is provided as 20 mg tablets, which can be cut in four 5 mg
pieces; dosage is often alternated (eg 10 mg one day and 5 the next). An estimate of the steady-
state dose for a given patient can be obtained through the following equations, where Css denotes
the average concentration that would be obtained for regular doses given every 24 hours, and
INRss denotes the steady-state INR that would be reached assuming the concentration remained
equal to Css:
Css =
D
24 CL
INRss =
I0
1− Imax
1 +
(
24 CL IC50
D
)γ


We used the second equation to predict INRss given a set of PK/PD parameters, for doses
ranging from 2.5 to 30 mg per day; a dose was considered to be adequate if INRss was within
the desired therapeutic range of 2-3. We also defined a recommended dose by using 1000 Monte-
Carlo simulations taking into account IIV; for each simulation, the recommended dose was the
dose yielding the INRss closest to 2.5. An associated probability is the percentage of simulations
recommending that dose.
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List of Figures
Figure 1: PKPD data collected in the 131 patients from the PREPA study: (top) concentration
of fluindione versus time in the study (in days); (bottom) INR versus time in the study. Dotted
lines delineate the therapeutic range for the patients in PREPA (2-3).
Figure 2: Goodness-of-fit plots: (top) observed versus predicted fluindione concentrations;
(bottom) observed versus predicted INR. The plots on the left were obtained with population
parameter estimates, while the plots on the right were obtained with individual parameter
estimates. The solid line represents the unity line around which points are expected to scatter
evenly.
Figure 3: Goodness-of-fit plots: npde with prediction intervals, for fluindione (left) and INR
(right) versus time (top) and predictions (bottom). The blue areas correspond to the prediction
intervals for the median (central band) and for the limits of the 95% prediction interval; the
thin dotted lines represent the predictions of the median and the limits, while the thick red lines
show the corresponding observed values.
Figure 4: Individual fits for 12 subjects, fluindione concentrations. Patient numbers starting
with 1 indicate patients recruited in the cardiology department, with 3 or 4 one of the two
geriatric departements, and with 5 the internal medicine department.
Figure 5: Individual fits for the same subjects, INR, superimposed with the daily dosing pattern
as vertical bars (scale for doses are on the right-hand axis).
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Table 1 : Demographic and biologic variables in the 131 patients from the PREPA study.
Variable
Median (range)
Age (yr) 85 (80-98)
Weight (kg, missing N=14) 65 (32-112)
ADL (-, missing N=6) 5.5 (1.5-6.5)
Creatinine clearance (ml/mn, missing N=3) 68 (11–179)
Gender Women: 87 (66%) Men: 44 (34%)
Surgery (cardiac surgery
before fluindione treatment) Yes: 52 (40%) No: 79 (60%)
Indication for fluindione
Atrial fibrillation 84 (64%)
Venous thromboembolism 27 (30%)
Heart valve prosthesis 43 (33%)
Most frequent comorbidities
Congestive heart disease 79 (60%)
Renal impairment 50 (38%)
Chronic pulmonary disease 28 (21%)
Peripheral vascular disease 22 (17%)
Diabetes 20 (15%)
Albumin (missing N=65) Normal (> 35): 29 30-35: 18 <30: 19
CRP (missing N=68) Normal (< 5): 13 5-50: 29 50-100: 13
≥ 100: 8
Absolute weight loss (missing N=14) 2-5 kg: 24 Over 5 kg: 21
Malnutrition (missing N=1) Yes: 27 No: 1031
Renal function (missing N=16) Normal: 27 Moderate: 66 Severe: 22
CYP2C9 *2 (missing N=86) Wild: 32 Het: 12 Mut: 1
CYP2C9 *3 (missing N=91) Wild: 31 Het: 7 Mut: 2
VKORC1 (missing N=89) CC: 11 CT: 21 TT: 10
1 for 76 subjects classified as not suffering from malnutrition and 10 with malnutrition, one or
several of the variables used to define malnutrition were missing and assumed normal
Table 2 : Parameter estimates for the PK/PD model without covariate (base model) and for
the final model. Interindividual variability is given as coefficient of variation (CV), and the
relative estimation error (RSE) is also shown.
Base model Final model
Parameter Mean (RSE %) CV % (RSE %) Mean (RSE %) CV % (RSE %)
ka (hr
−1) 2.42 (-) - 2.42 (-) -
V (L) 9.06 (5) 41 (10) 8.24 (5) 36 (10)
βV,men - - 0.24 (41) -
βV,weight - - 0.57 (35) -
CL (L.hr−1) 0.12 (5) 47 (8) 0.10 (8) 42 (8)
βCL,age - - -3.26 (30) -
βCL,cordarone - - -0.18 (49) -
I0 (-) 1.11 (2) 10 (21) 1.10 (2) 7 (31)
kout (hr
−1) 0.03 (14) 80 (15) 0.03 (13) 85 (13)
IC50 (mg.L
−1) 1.71 (10) 56 (10) 2.18 (11) 53 (10)
βIC50,surgery - - -0.54 (25) -
Imax (-) 0.89 (6) - 0.94 (7) -
γ (-) 1.70 (15) 53 (16) 1.71 (15) 40 (21)
βγ,surgery - - -0.46 (34) -
βγ,deroxat - - 0.88 (31) -
aPK (mg.L
−1) 0.19 (15) - 0.20 (14) -
bPK (-) 0.09 (16) - 0.08 (17) -
bPD (-) 0.14 (5) - 0.13 (5) -
Removed: 1 weight was centered on 60 kg
Removed: 2 age was centered on 90 yr
The following parameter-covariate relationships were estimated, with i denoting the individual:
Vi = V
(
WEIGHTi
60
)βV,weight
Men
βV,men
i e
ηV,i
CLi = CL
(
AGEi
90
)βCL,age
Cordarone
βCL,cordarone
i e
ηCL,i
IC50,i = IC50 Surgery
βIC50,surgery
i e
ηIC50,i
γi = γ Surgery
βγ,surgery
i Deroxat
βγ,deroxat
i e
ηγ,i
(7)
where for instance Meni is 1 if i is a man and 0 if a woman. Weight was centered on 60 kg,
while age was centered on 90 yr.
Table 3 : Recommended dose depending on different patient profiles, defined as the dose
yielding a steady-state value closest to 2.5. The last column represents the percentage of time
that the corresponding dose is selected over the 1000 Monte-Carlo simulations performed, to
take into account the IIV.
Profile Recommended dose (mg) Probability
80 year old man, 60 kg 7.5 17%
80 year old woman, 60 kg 7.5 17%
80 year old man, 50 kg 7.5 16%
80 year old man, 70 kg 10 17%
90 year old man, 60 kg 5 22%
80 year old man, 60 kg, after cardiac surgery 5 24%
80 year old man, 60 kg, given cordarone 5 22%
80 year old man, 60 kg, given deroxat 5 19%
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Supplementary material
Analytical methods
Analytical methods. For patients recruited in the Bichat and Angers university hospi-
tals, INR was assayed on-site in the corresponding Laboratoire d’He´mostase, which both use a
STARE coagulometer (Diagnostica Stago, 92600 Asnie`res, France) and thromboplastin STA R©-
Neoplastin CI with an international sensitivity index (ISI) of 1.63 (batch number 100675, Diag-
nostica Stago) during the whole study. The samples from the 4 patients in the Beaujon hospital
were centralised at the Bichat hospital. INR was calculated from the prothrombin time (PT)
as:
INR =
(
Patient PT
mean normal PT
)ISI
(8)
The two Laboratoires d’He´mostase both perform routine controls, which included for the study
period successively C06, C07, C08 (Asqualab, Stago) that were daily checked on the coagulome-
ter. PT coefficient of variation was between 1.7-2.4% during this period.
Determination of fluindione concentrations. The samples for the measurement of fluin-
dione concentrations were frozen at -20◦C, and shipped at regular intervals throughout the study
to the Laboratoire de Pharmacologie-Toxicologie in the Angers university hospital. Plasma
fluindione was assayed with use of an HPLC–UV system Surveyor (ThermoFinnigan), with
ChromQuest software [48]. The UV spectrophotometer was set at a wavelength of 280 nm .The
separation was achieved at 40◦C temperature, with a reversed-phase 100X 4.6 mm internal di-
ameter BetaBasic-8 column and 5 µm particle size packing (ThermoElectron). The mobile phase
composition was optimized to a 0.067 mol.L−1 dibasic sodium phosphate buffer (adjusted to pH
6.3 with phosphoric acid) and acetonitrile (82:18, vol/vol) mixture. The flow rate was set at
1.5 mL.min−1.The following extraction procedure was used: 100 µ1 of plasma from human hep-
arinized blood (spiked plasma used for calibration and controls; patients’ plasma samples) was
added to a 1.5 ml tube that contained 50 µL of 20 mg.L−1 internal standard solution (warfarin)
and 100 µL acetonitrile. The tube was vortexed for 30 seconds and centrifuged for 10 minutes at
3000g. A 150 µL volume of supernatant was transferred to another tube that contained 200 µL
of phosphate buffer; 25 µL of the mixture was injected into the HPLC system. The calibra-
tion curve was linear over the range 0.05 to 6 mg.L−1. The method was highly reproducible.
The coefficient of variation was 6.1% for a fluindione concentration of 0.1 mg.L−1, 2.8% for a
concentration of 0.5 mg.L−1, and 2.3% for a concentration of 4 mg.L−1 (10 measurements for
each concentration). The estimated limit of quantification was 0.1 mg.L−1 under the conditions
described above, with a signal-to-noise ratio of 3 and a coefficient of variation lower than 20%.
Determination of genetic polymorphisms. DNA was extracted from the blood samples
of patients consenting to the genetic ancillary study. For patients from the Bichat university
hospital, the sample was directly sent to the Centre de Ressources Biologiques (CRB, DNA
bank) of the hospital, and the DNA was extracted. For patients from the other two hospitals,
samples were frozen at -20◦C and sent every 3 months to the CRB for extraction and storage.
CYP2C9*2 and CYP2C9*3 (rs number 1799853 and 1057910, respectively) as well as VKORC1
genetic polymorphism for the 1173 C>T (rs number 9934438) were determined using custom
Taq Man allelic discrimination assays (Applied Biosystems, Foster City, CA, USA) as in [40, 28].
They were performed all together at the end of study. The post-PCR-generated fluorescence
intensity was quantified using an ABI 7000 Sequence detector System software version 1.2.3
(Applied Biosystems, Courtaboeuf, France). Each SNP genotyping procedure was performed in
duplicate (separate experiments) for each patient. In cases of discordant results, samples were
analyzed by DNA sequencing to confirm the genotype. Sequenced wild-type, homozygous and
heterozygous patient samples were used as controls. All PCR reagents were purchased from
Applied Biosystems.
We chose the VKORCI 1173 C>T SNP (rs9934438) to identify the major VKORCI haplotype
groups A and B. The C allele of the 1173 C>T SNP corresponds to the group B VKORCI
haplotype and the T allele to the group A VKORCI haplotype. This SNP is in complete linkage
disequilibrium with at least four other SNPs, which all individually allow the identification of
VKORCI haplotype groups [49, 50], which has been previously confirmed in a White French
population [40].
Assessing model sensitivity
The PREPA study was an observational study, and to minimise the burden on patients, sam-
ples were taken only at the usual time for therapeutic monitoring. Figure S1 shows the dose-
normalised fluindione concentrations versus time after the dose. Several patients skipped one
or several doses, usually because the clinician was concerned about a quick rise in the INR,
therefore for these patients the time after dose exceeds 24 hours, but most samples were taken
10 to 16 hours after the dose. The main plot displays the whole dataset, while the inset shows
a zoom for time after dose lower than 48 hours, in order to better show the variability. Note
that concentrations were normalised to the last dose taken before the measurement, so that for
patients with changing doses the apparent variability may be larger since it does not take into
account the whole dosing history. This figure shows that most of the samples were clustered
between 10 and 15 hours.
Because there was concern regarding the ability of this design to properly estimate the
parameters of the model, and also in light of the discrepancy with the results previously found
in the ADAP study, we performed a small study to assess the robustness of the parameter
estimates. Due to time constraints this study was performed only for the PK model. We
simulated 20 datasets with the population parameters estimated in the ADAP study and 20
datasets with the parameters estimated with the base model (without covariates) in the PREPA
study. We then estimated the parameters of the PK model starting with initial estimates close to
those of the ADAP study. The results are displayed in Supplementary Table S3, and show that
despite the sparse design, the parameter estimates in both cases are close to the simulated values.
There was more variability in the estimates from the datasets simulated with the parameters
from the ADAP study (25% variability between runs versus 5%), partly because the IIV was
larger in ADAP than in PREPA, but it was possible to clearly distinguish between the two sets
of parameters.
Supplementary tables
Table S1: Drug classification used for the covariate analysis of the comedications in the PREPA
study (from reference [42]).
Drugs increasing the thrombotic risk
A1 enzymatic inducers (decreasing INR)
A2 other drugs inhibiting coagulation
Drugs increasing the haemorragic risk
B11 anti-vitamin K agents
B12 aspirin, non-steroidal anti-inflammatory drugs
B13 heparins
B14 other drugs
B21 enzymatic inhibitors
B22 antibiotics with a negative effect on the intestinal flora
B23 drugs acting through another mechanism
Table S2: Range of parameter estimates for the covariate effects, obtained by multiple impu-
tation (K=5 imputed datasets), compared to the estimate in the dataset where missing weight
is imputed to the mean value.
Parameter Estimate Range MI
βV,men 0.24 (41) [0.17 – 0.25]
βV,weight 0.57 (35) [0.51 – 0.63]
βCL,age -3.26 (30) [-3.38 – -2.96]
βCL,cordarone -0.18 (49) [-0.19 – -0.17]
βC50,surgery -0.54 (25) [-0.75 – -0.52]
βγ,surgery -0.46 (34) [-0.68 – -0.50]
βγ,deroxat 0.88 (31) [0.81 – 2.03]
Table S3: Results from the simulation study: PK parameter estimates obtained on N=20
datasets simulated with the design of the original study, under two different set of parameters,
ADAP=parameters estimated in the ADAP study [25]; PREPA=parameters estimated in the
current study, with the base model (no covariates). We show the median and range of the
parameters estimated in the 20 datasets for each simulation.
Parameter ADAP PREPA
Simulated Estimated Simulated Estimated
Median [range] Median [range]
V (L) 37.1 38.8 [23.0–65.3] 9.06 9.38 [8.73–10.20]
CL (L.hr−1) 0.49 0.42 [0.26–0.74] 0.12 0.12 [0.10–0.14]
Supplementary figure
Figure S1: Dose-normalised fluindione concentrations versus time after dose. Main plot: whole
dataset; Inset: zoom for time after dose lower than 48 hours. When dose changes occurred, the
last non-null dose before the measurement was taken for normalising.
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